AbbVieABBV
ABBV
About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Employees: 50,000
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
201% more first-time investments, than exits
New positions opened: 394 | Existing positions closed: 131
5% more funds holding
Funds holding: 3,448 [Q3] → 3,635 (+187) [Q4]
1.69% more ownership
Funds ownership: 70.35% [Q3] → 72.04% (+1.69%) [Q4]
7% more repeat investments, than reductions
Existing positions increased: 1,479 | Existing positions reduced: 1,380
6% more call options, than puts
Call options by funds: $3.18B | Put options by funds: $2.99B
5% less capital invested
Capital invested by funds: $244B [Q3] → $232B (-$12.2B) [Q4]
20% less funds holding in top 10
Funds holding in top 10: 207 [Q3] → 165 (-42) [Q4]
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$190
9%
upside
Avg. target
$216
24%
upside
High target
$241
39%
upside
11 analyst ratings
8 positive
73%
3 neutral
27%
0 negative
0%
Cantor Fitzgerald Carter Gould 29% 1-year accuracy 9 / 31 met price target | 21%upside $210 | Overweight Initiated | 22 Apr 2025 |
Guggenheim Vamil Divan 27% 1-year accuracy 8 / 30 met price target | 23%upside $214 | Buy Reiterated | 17 Apr 2025 |
Morgan Stanley Terence Flynn 24% 1-year accuracy 5 / 21 met price target | 39%upside $241 | Overweight Maintained | 9 Apr 2025 |
Goldman Sachs Asad Haider 100% 1-year accuracy 2 / 2 met price target | 12%upside $194 | Neutral Assumed | 8 Apr 2025 |
Wells Fargo Mohit Bansal 30% 1-year accuracy 8 / 27 met price target | 38%upside $240 | Overweight Maintained | 5 Mar 2025 |
Financial journalist opinion
Based on 74 articles about ABBV published over the past 30 days
Neutral
CNBC Television
11 hours ago
Final Trades: 3M, Abbvie, Salesforce and Intuitive Surgical
The Investment Committee give you their top stocks to watch for the second half.
Neutral
Barrons
14 hours ago
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom
Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.
Positive
Zacks Investment Research
15 hours ago
Seeking Clues to AbbVie (ABBV) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for AbbVie (ABBV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Positive
Zacks Investment Research
15 hours ago
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
Neutral
PRNewsWire
19 hours ago
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders
NEW YORK , April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud.
Neutral
GlobeNewsWire
1 day ago
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors – Contact Levi & Korsinsky
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.
Positive
FXEmpire
1 day ago
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Neutral
PRNewsWire
1 day ago
The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ABBV
NEW YORK , April 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Neutral
The Motley Fool
2 days ago
Is AbbVie Stock a Buy?
It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (ABBV 0.62%). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to failed its clinical trials.
Neutral
GlobeNewsWire
4 days ago
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights – ABBV
NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.
Charts implemented using Lightweight Charts™